Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 2

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361 · tracked via the Priya Life Science USA tracker
Phase
Phase 2
Started
2026-06-23
Last updated
2026-10-15

Condition(s) studied

HypertensionAcute Severe HypertensionHypertensive EmergencyHypertensive Urgency

Investigational drug(s) / intervention(s)

TonlamarsenPlacebo

Tonlamarsen: Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

Placebo: Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

Study summary

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2 * Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization * At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg * Presence of established cardiovascular or renal disease Key Exclusion Criteria: * Has known history of secondary hypertension * Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated) * Has abnormal thyroid function with clinical significance * Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening * History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease * Alanine aminotransferase or aspartate aminotransferase \>2 x upper limit of normal * Most recent hospitalization was for non-cardiovascular or non-renal conditions

Primary outcome measure(s)

  • Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions — Baseline through Week 12
    * Change from baseline in plasma angiotensinogen (AGT) levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure
  • Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels — Week 4
    Percent change in plasma AGT levels from Baseline to Week 4

Trial sites (13)

FacilityCityRegionStatus
Western Nephrology and Metabolic Bone Disease, PC - Arvada Arvada Colorado Recruiting
Homestead Associates in Research Homestead Florida Recruiting
Progressive Medical Research Port Orange Florida Recruiting
Eagle Clinical Research Chicago Illinois Recruiting
Henry Ford Hospital Detroit Michigan Recruiting
Richmond University Medical Center (RUMC) Staten Island New York Active Not Recruiting
Research Innovations, LLC Beavercreek Ohio Recruiting
Cleveland Clinic Cleveland Ohio Recruiting
OnSite Clinical Solutions, LLC Fort Mill South Carolina Recruiting
Chattanooga Research & Medicine CHARM Chattanooga Tennessee Recruiting
Laguna Clinical Research Associates Laredo Texas Recruiting
Tapia Internal Medicine Clinic Paris Texas Recruiting
Baylor Scott and White Research Institute - Temple Temple Texas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511361 on ClinicalTrials.gov ↗ ← All trials in the USA